The lipid triad, or how to reduce residual cardiovascular risk?
Girard-Mauduit
S
S
Service d'endocrinologie-diabétologie, hôpital Ambroise-Paré, 9 avenue Charles-de-Gaulle, Boulogne-Billancourt, France. stephanie.mauduit@gmail.com
D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D050197:Atherosclerosis / Q000188:drug therapy / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D015201:Meta-Analysis as Topic; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D009765:Obesity / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D015995:Prevalence; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D014280:Triglycerides